VJLabs @ Terasaki Institute awarded NIH R21 grant to advance xenotransplantation research using organ-on-a-chip technology
Grant and Award Announcement
Updates every hour. Last Updated: 8-Apr-2026 11:16 ET (8-Apr-2026 15:16 GMT/UTC)
Los Angeles, CA –February 23, 2026 – Dr. Vadim Jucaud, Principal Investigator and Assistant Professor at the Terasaki Institute, with Co-Principal Investigator Angeles Baquerizo, MD, PhD, FACS, FAASLD have been awarded an NIH R21 research grant to develop a first-of-its-kind organ-on-a-chip platform to study immune rejection in pig-to-human liver transplantation. The project tackles one of the most pressing challenges in modern transplantation medicine: advancing xenotransplantation toward safe and effective clinical use.
The Business Technology Department ranked No. 1 in the nation for research, a prestigious recognition that places the University of Miami at the very top of the information systems discipline for the first time.
Researchers at the University of Oulu, Finland, have developed new high-performance bio-based resins that can replace conventional oil-based materials in composite products — without compromising strength, cost, or industrial scalability.
By studying a bacterium responsible for a severe heart infection, the scientists show that disrupting bacterial communication can be associated with adverse clinical outcomes. Published in Nature Communications, these findings open the door to more targeted – and potentially more effective – therapeutic strategies against this type of infection. A team from NTU’s SCELSE (Singapore Centre for Environmental Life Sciences and Engineering), a multidisciplinary biofilm and microbiome research centre, and UNIGE’s Faculty of Medicine is challenging a widely held assumption in infectious disease research: that blocking bacterial communication is always beneficial. Scientists found that when Enterococcus faecalis can no longer communicate with neighbouring bacteria, it forms larger, more resilient biofilms on heart valves, resulting in more severe clinical outcomes.